The US government this week took the rare step of suing Gilead for infringing on four government-owned patents related to the HIV drug Truvada for pre-exposure prophylaxis (PrEP), according to a complaint filed in Delaware’s district court. The patents at issue were the result of the Centers for Disease Control and Prevention’s (CDC) research on emtricitabine (FTC)/tenofovir and FTC/tenofovir prodrug regimens for PrEP. But the complaint alleges that not only did the offices within the National Institutes of Health try to enter into a licensing agreement with Gilead in 2017 and 2018 and fail to reach a deal, but that Gilead acted in a questionable manner throughout. Learn More